DC vaccines targeting Wilms’ tumor 1 (WT1) have been previously shown to be safe and feasible with few adverse reactions in patients with advanced cancer, including colorectal cancer [12], pancreatic cancer [13,14], lung cancer [15], high-grade glioma [16], and pediatric cancer [17,18]. This evidence concerns the gene WT1 and familial pancreatic carcinoma.